TRAF6 and psoriasis: Oroxylin A has been demonstrated to demonstrate remarkable precision by specifically targeting the critical p62-TRAF6 interface to effectively block TRAF6 oligomerization and K63 ubiquitination, thereby inhibiting the NF-κB/NLRP3 inflammatory axis in psoriasis models (130).